Abbott announced that the FDA approved a closure device for the treatment of premature babies with patent ductus arteriosus who are nonresponsive to medical management. The Amplatzer Piccolo occluder ...
The cyclooxygenase inhibitor ibuprofen may be used to treat patent ductus arteriosus (PDA) in preterm infants. Whether selective early treatment of large PDAs with ibuprofen would improve short-term ...
DENVER, April 22, 2022 – A randomized controlled trial evaluates if selective early treatment of patent ductus arteriosus reduces death or bronchopulmonary dysplasia at 36 weeks in extreme preterm ...
Merit Medical Systems initiates a study to evaluate the Bloom Micro Occluder System for treating patent ductus arteriosus in premature infants. Merit Medical Systems, Inc. has announced the enrollment ...
The multicentre, randomised, double-blind, placebo-controlled Baby-OSCAR trial. Participants were 653 extremely preterm infants with a large patent ductus arteriosus (diameter, ≥ 1.5 mm). In the first ...
Active treatment of hemodynamically significant patent ductus arteriosus (PDA) in preterm infants within the first 2 weeks of life was associated with worse outcomes than expectant management, a ...
For extremely preterm infants who have a large patent ductus arteriosus, early treatment with ibuprofen may reduce the risk of death and improve short-term outcomes. New research findings are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback